JP6869968B2 - Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 - Google Patents

Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 Download PDF

Info

Publication number
JP6869968B2
JP6869968B2 JP2018514962A JP2018514962A JP6869968B2 JP 6869968 B2 JP6869968 B2 JP 6869968B2 JP 2018514962 A JP2018514962 A JP 2018514962A JP 2018514962 A JP2018514962 A JP 2018514962A JP 6869968 B2 JP6869968 B2 JP 6869968B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
binding fragment
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018514962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535650A5 (https=
JP2018535650A (ja
Inventor
ダヴィデ・コルティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Publication of JP2018535650A publication Critical patent/JP2018535650A/ja
Publication of JP2018535650A5 publication Critical patent/JP2018535650A5/ja
Priority to JP2021068062A priority Critical patent/JP7171809B2/ja
Application granted granted Critical
Publication of JP6869968B2 publication Critical patent/JP6869968B2/ja
Priority to JP2022175909A priority patent/JP2023011809A/ja
Priority to JP2024074160A priority patent/JP2024097078A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018514962A 2015-10-07 2016-10-07 Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 Active JP6869968B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021068062A JP7171809B2 (ja) 2015-10-07 2021-04-14 Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
JP2022175909A JP2023011809A (ja) 2015-10-07 2022-11-02 Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
JP2024074160A JP2024097078A (ja) 2015-10-07 2024-05-01 Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2015/001970 2015-10-07
PCT/EP2015/001970 WO2017059878A1 (en) 2015-10-07 2015-10-07 Antibodies that potently neutralize hepatitis b virus and uses thereof
PCT/EP2016/074114 WO2017060504A1 (en) 2015-10-07 2016-10-07 Antibodies that potently neutralize hepatitis b virus and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021068062A Division JP7171809B2 (ja) 2015-10-07 2021-04-14 Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2018535650A JP2018535650A (ja) 2018-12-06
JP2018535650A5 JP2018535650A5 (https=) 2019-10-31
JP6869968B2 true JP6869968B2 (ja) 2021-05-12

Family

ID=54330711

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018514962A Active JP6869968B2 (ja) 2015-10-07 2016-10-07 Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
JP2021068062A Active JP7171809B2 (ja) 2015-10-07 2021-04-14 Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
JP2022175909A Withdrawn JP2023011809A (ja) 2015-10-07 2022-11-02 Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
JP2024074160A Pending JP2024097078A (ja) 2015-10-07 2024-05-01 Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021068062A Active JP7171809B2 (ja) 2015-10-07 2021-04-14 Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
JP2022175909A Withdrawn JP2023011809A (ja) 2015-10-07 2022-11-02 Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
JP2024074160A Pending JP2024097078A (ja) 2015-10-07 2024-05-01 Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用

Country Status (24)

Country Link
US (3) US10683344B2 (https=)
EP (2) EP3359564B1 (https=)
JP (4) JP6869968B2 (https=)
KR (1) KR102725168B1 (https=)
CN (3) CN114539392B (https=)
AU (1) AU2016334735B2 (https=)
BR (1) BR112018002406A2 (https=)
CA (1) CA2993745A1 (https=)
CY (1) CY1123462T1 (https=)
DK (1) DK3359564T3 (https=)
EA (1) EA038301B1 (https=)
ES (1) ES2813927T3 (https=)
HR (1) HRP20201345T1 (https=)
HU (1) HUE050231T2 (https=)
IL (1) IL258326B (https=)
LT (1) LT3359564T (https=)
MX (1) MX2018004127A (https=)
MY (1) MY187161A (https=)
PH (1) PH12018500199A1 (https=)
PL (1) PL3359564T3 (https=)
PT (1) PT3359564T (https=)
SI (1) SI3359564T1 (https=)
WO (2) WO2017059878A1 (https=)
ZA (1) ZA201800710B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023011809A (ja) * 2015-10-07 2023-01-24 ヒューマブス バイオメド エスエー Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3810625B1 (en) * 2018-05-10 2024-05-22 Clearb Therapeutics Ltd. Methods and compositions for the treatment of hepatitis b infection
US20210214424A1 (en) * 2018-05-16 2021-07-15 Chang Gung Memorial Hospital, Linkou Novel leucine-rich repeat neuronal protein 1 (lrrn1) antibodies and uses thereof
EP3801766A1 (en) * 2018-05-31 2021-04-14 Novartis AG Hepatitis b antibodies
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
FI3898668T3 (fi) * 2018-12-19 2023-11-28 Humabs Biomed Sa B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä
RS67553B1 (sr) * 2018-12-20 2026-01-30 Humabs Biomed Sa Kombinovana hbv terapija
KR102084912B1 (ko) * 2019-01-17 2020-03-05 주식회사 녹십자 B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체
JP2022542035A (ja) * 2019-07-20 2022-09-29 フアフイ ヘルス リミテッド 抗ｐｒｅ－ｓ１ ｈｂｖ抗体を用いるｈｂｖ感染症の治療方法
CA3152511A1 (en) * 2019-08-29 2021-03-04 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
CN113717283B (zh) * 2020-05-25 2023-05-26 厦门万泰凯瑞生物技术有限公司 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用
JP7579007B2 (ja) * 2020-06-02 2024-11-07 株式会社Rcmg Ｈｂｖの抗ｒｎａウイルス粒子抗体
PE20240080A1 (es) * 2020-06-08 2024-01-16 Hoffmann La Roche Anticuerpos anti-hbv y metodos de uso
EP4168547A1 (en) * 2020-06-22 2023-04-26 Janssen Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis d virus infection
PH12022553569A1 (en) * 2020-06-24 2023-04-12 Humabs Biomed Sa Engineered hepatitis b virus neutralizing antibodies and uses thereof
TWI868379B (zh) * 2020-07-09 2025-01-01 大陸商北京凱因科技股份有限公司 結合ｂ型肝炎病毒表面抗原的抗體及其應用
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP2024504167A (ja) 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
CN113234144B (zh) * 2021-05-26 2022-02-25 武汉工程大学 一种人源性抗乙肝表面抗原的单链抗体、制剂、编码基因、载体质粒及宿主细胞
WO2023287352A2 (en) * 2021-07-15 2023-01-19 National University Of Singapore Anti-hbv antibodies and uses thereof
CN113777312B (zh) * 2021-09-03 2024-02-02 普十生物科技(北京)有限公司 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用
US20240391979A1 (en) * 2021-09-13 2024-11-28 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
CA3242060A1 (en) * 2021-12-21 2023-06-29 Hbvtech, Llc. Methods for eliminating hepatitis b virus cccdna and rcdna and the hepatitis b drugs used in the methods thereof
TW202411246A (zh) 2022-05-23 2024-03-16 美商維爾生物科技股份有限公司 經工程化之b型肝炎病毒中和抗體及其用途
CN116162153B (zh) * 2022-09-01 2024-09-10 复旦大学附属中山医院 一种乙肝病毒表面抗原的单克隆抗体及其应用
CN118725092B (zh) * 2023-03-28 2025-08-12 东莞市朋志生物科技有限公司 抗HBs-Ag抗体、检测HBs-Ag的试剂和试剂盒
AU2024279207A1 (en) * 2023-05-31 2025-10-16 Bluejay Therapeutics, Inc. Anti-hbsag antibody for treatment of chronic hepatitis d
CN119143869A (zh) * 2023-06-16 2024-12-17 复旦大学 乙肝病毒表面抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1997039029A2 (en) 1996-04-18 1997-10-23 Abbott Laboratories An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
JP2001508054A (ja) * 1996-12-30 2001-06-19 イノジェネティックス・ナムローゼ・フェンノートシャップ ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
CA2594922A1 (en) * 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
KR20090056537A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물
PL2350128T3 (pl) 2008-10-22 2015-03-31 Inst Res Biomedicine Sposoby wytwarzania przeciwciał z komórek plazmatycznych
SG11201501255PA (en) * 2012-08-30 2015-03-30 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections
CN104955837A (zh) * 2012-11-12 2015-09-30 海德堡吕布莱希特-卡尔斯大学 Hbv和/或hdv易感细胞、细胞系和非人动物的开发
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023011809A (ja) * 2015-10-07 2023-01-24 ヒューマブス バイオメド エスエー Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
US12037381B2 (en) 2015-10-07 2024-07-16 Humabs Biomed Sa Antibodies that potently neutralize hepatitis B virus and uses thereof

Also Published As

Publication number Publication date
SI3359564T1 (sl) 2020-10-30
LT3359564T (lt) 2020-10-26
US10683344B2 (en) 2020-06-16
AU2016334735B2 (en) 2022-10-27
EP3359564A1 (en) 2018-08-15
DK3359564T3 (da) 2020-08-17
ES2813927T3 (es) 2021-03-25
CA2993745A1 (en) 2017-04-13
EP3753949A1 (en) 2020-12-23
CY1123462T1 (el) 2022-03-24
EP3359564B1 (en) 2020-06-03
NZ739360A (en) 2024-10-25
EA038301B1 (ru) 2021-08-06
PT3359564T (pt) 2020-09-04
ZA201800710B (en) 2019-05-29
CN108137675A (zh) 2018-06-08
PH12018500199A1 (en) 2018-08-13
KR102725168B1 (ko) 2024-10-31
PL3359564T3 (pl) 2020-11-30
CN114539391A (zh) 2022-05-27
BR112018002406A2 (pt) 2018-09-18
WO2017060504A1 (en) 2017-04-13
CN108137675B (zh) 2022-03-22
CN114539392A (zh) 2022-05-27
EA201890874A1 (ru) 2018-11-30
CN114539392B (zh) 2024-01-26
US20230303663A1 (en) 2023-09-28
JP2021121188A (ja) 2021-08-26
US20210040183A1 (en) 2021-02-11
MY187161A (en) 2021-09-06
HRP20201345T1 (hr) 2020-11-27
IL258326B (en) 2021-10-31
JP2024097078A (ja) 2024-07-17
HUE050231T2 (hu) 2020-11-30
MX2018004127A (es) 2018-06-13
WO2017059878A1 (en) 2017-04-13
US12037381B2 (en) 2024-07-16
JP2023011809A (ja) 2023-01-24
KR20180056777A (ko) 2018-05-29
US20190016785A1 (en) 2019-01-17
JP2018535650A (ja) 2018-12-06
US11390664B2 (en) 2022-07-19
IL258326A (en) 2018-05-31
JP7171809B2 (ja) 2022-11-15
AU2016334735A1 (en) 2018-02-15
HK1256869A1 (en) 2019-10-04

Similar Documents

Publication Publication Date Title
JP6869968B2 (ja) Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
US20250353900A1 (en) Antibodies that neutralize hepatitis b virus and uses thereof
CN114630680B (zh) 用于治疗乙型肝炎病毒感染的抗体组合物和方法
JP2024504167A (ja) Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
HK40074417A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074418A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074418B (zh) 中和乙型肝炎病毒的抗体和其用途
HK40037903A (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
HK1256869B (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
HK40056051A (en) Antibodies that neutralize hepatitis b virus and uses thereof
CN117042797A (zh) 用于治疗乙型肝炎病毒感染的组合物和方法
HK40073510B (zh) 用於治疗乙型肝炎病毒感染的抗体组合物和方法
HK40056051B (zh) 中和乙型肝炎病毒的抗体和其用途

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210316

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210414

R150 Certificate of patent or registration of utility model

Ref document number: 6869968

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250